Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Gun Violence Trauma
  • Maternal Mortality
  • Hospital Food
  • Medicaid Work Requirements
  • Visa Program Delays

TRENDING TOPICS:

  • Gun Violence Trauma
  • Maternal Mortality
  • Hospital Food
  • Medicaid Work Requirements
  • Visa Program Delays

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Feb 12 2018

Full Issue

Deputy White House Chief Of Staff Tapped To Lead Office In Charge Of Tackling Opioid Crisis

Jim Carroll has no background in working in public health policy, but the White House said that after law school, Carroll spent five years as the assistant commonwealth attorney for Fairfax, Virginia, where the majority of the cases were drug-related.

The Associated Press: Trump To Nominate Jim Carroll As Next Drug Czar

President Donald Trump has tapped deputy White House chief of staff Jim Carroll to serve as the administration's next drug czar. Carroll's position as head of the Office of National Drug Control Policy will make him the most public face of the administration's efforts to fight the opioid epidemic — an effort critics say hasn't gone nearly far enough. (2/9)

The Washington Post: White House Official Nominated As Nation's Drug Czar

Jim Carroll would be the first Trump appointee to lead the Office of National Drug Control Policy. Trump’s first pick, Rep. Tom Marino (R-Pa.), withdrew his nomination after The Washington Post reported that he was the chief advocate of a law that weakened DEA enforcement against drug manufacturers who aggressively peddled opioids. The office has been leaderless despite Trump calling the opioid epidemic one of his top priorities. He declared it a public health emergency in October, a designation that was extended last month. But the White House has offered no concrete solutions on how to solve the crisis, and little has happened in the months since the declaration was made. (Zezima, 2/9)

The Hill: Kelly Deputy Named Drug Czar

Trump's first nominee for that post, Rep. Tom Marino (R-Penn.), withdrew last year after it was revealed that he had helped guide legislation that critics argue makes it harder for the Drug Enforcement Administration to freeze suspicious shipments of opioids. (Greenwood, 2/9)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 4
  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF